Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off […]
WISeKey Announces Retirement of Peter Ward as Chief Financial Officer; Appoints John O’Hara as its New Chief Financial Officer
WISeKey Announces Retirement of Peter Ward as Chief Financial Officer; Appoints John O’Hara as its New Chief Financial Officer Geneva, […]
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activators Preclinical safety, efficacy, and […]
